» Articles » PMID: 30852045

Well-differentiated Liposarcoma and Dedifferentiated Liposarcoma: An Updated Review

Overview
Date 2019 Mar 11
PMID 30852045
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Well-differentiated liposarcoma (WDL)/atypical lipomatous tumor and dedifferentiated liposarcoma (DDL) together comprise the largest subgroup of liposarcomas, and constitute a histologic and behavioral spectrum of one disease. WDL and DDL typically occur in middle-aged to older adults, particularly within the retroperitoneum or extremities. WDL closely resembles mature adipose tissue, but typically shows fibrous septation with variable nuclear atypia and enlargement. WDL does not metastasize, but can dedifferentiate to DDL, which is associated with more aggressive clinical behavior, with a greater propensity for local recurrence and the capacity for metastasis. Although distant metastasis is rarer in DDL compared with other pleomorphic sarcomas, behavior is related to location, with a significantly worse outcome in retroperitoneal tumors. DDL typically has the appearance of undifferentiated pleomorphic or spindle cell sarcoma, and is usually a non-lipogenic sarcoma that is adjacent to WDL, occurs as a recurrence of WDL or which can arise de novo. WDL and DDL share similar background genetic aberrations; both are associated with high-level amplifications in the chromosomal 12q13-15 region, which includes the CDK4 and MDM2 cell cycle oncogenes. In addition, DDL harbor further genetic changes, particularly 6q23 and 1p32 coamplifications. While surgical excision remains the treatment mainstay with limited medical options for patients with aggressive recurrent disease or metastases, novel targeted therapies towards the gene products of chromosome 12 are being evaluated. This review summarizes the pathology of WDL and DDL, discussing morphology, immunohistochemistry, genetics and the differential diagnosis.

Citing Articles

Imaging, clinical, and histopathological challenges in diagnosing retroperitoneal extraskeletal osteosarcoma.

Ichikawa J, Kawasaki T, Onohara K, Wako M, Taniguchi N, Ochiai S Front Oncol. 2025; 15:1454055.

PMID: 40078181 PMC: 11896851. DOI: 10.3389/fonc.2025.1454055.


Dedifferentiated liposarcoma of transverse colon: a case report and review of the literature.

Hawkins N, Mushaya C J Surg Case Rep. 2025; 2025(3):rjaf097.

PMID: 40051808 PMC: 11881694. DOI: 10.1093/jscr/rjaf097.


"Enhancing Liposarcoma Prognosis - A New Predictive Scoring System Integrating Histopathological Insights".

Ciongariu A, Tapoi D, Dumitru A, Enache V, Marin A, Creanga C Cancer Manag Res. 2025; 17:331-348.

PMID: 39990278 PMC: 11844267. DOI: 10.2147/CMAR.S504889.


Primary giant liposarcoma of the gallbladder: a case report and literature review.

Yang Y, Hou Y, Yi L, Chen C, Tang L, Hu M World J Surg Oncol. 2025; 23(1):61.

PMID: 39987143 PMC: 11846246. DOI: 10.1186/s12957-025-03711-7.


The G-quadruplex experimental drug QN-302 impairs liposarcoma cell growth by inhibiting MDM2 expression and restoring p53 levels.

Tosoni B, Naghshineh E, Zanin I, Gallina I, Di Pietro L, Cleris L Nucleic Acids Res. 2025; 53(4).

PMID: 39945321 PMC: 11822379. DOI: 10.1093/nar/gkaf085.